CCP-LPP
(Comprehensive Cardiac Profile-Lipoprotein Particle Profile)
The CCP-LPP is a comprehensive profile of lipoprotein particles, lipids and vascular inflammation markers. It is used to identify people who are at risk for cardiovascular problems. This test is unique and is seldom done by your doctor because insurance rarely pays for it.
Knowing your customized results for the YFH CCP test (including Homocysteine, C-Reactive Protein and Fasting Insulin) along with the Omega 3 Profile + test can change your future risk of heart disease. Taking the correct amount and type of fish oil is critical. Doing both tests at the same time provides the data to adjust your Omega3 intake. Making this adjustment can change your scores and reduce your risk factors in just two weeks.
Understanding Cholesterol and Lipoprotein
Cholesterol has historically been used as the standard indicator for cardiovascular disease, often being classified as “good” (HDL), or “bad” (LDL). Studies have found that it is actually the lipoprotein particles that carry the cholesterol through the blood, not the cholesterol within them, that are responsible for key steps in plaque formation and the development of cardiovascular disease. The small, dense, cholesterol-depleted particles impart the highest risk, as does an increased number of these lipoproteins. Standard cholesterol testing does not tell us enough about the particle types—or subgroups—of each of these LDL and HDL families; therefore, it misses the earliest opportunity to prevent adverse cardiovascular events, when it is easiest to treat.
Cardiovascular risk increases with a higher LDL particle count. The probability of particle penetration of the arterial walls rises, regardless of the total amount of cholesterol contained in each particle.
More than 30% of the population has cholesterol-depleted LDL, a condition in which a patient’s cholesterol may be “normal” but their lipoprotein particle number, and hence their actual risk, could be much higher than expected. This is especially common in people whose triglycerides are high or HDL is low.
There are twenty specific measures in this test. They include eight Lipoprotein Particle Markers, five Lipid Panel Markers and seven Vascular Inflammation Markers.
Cardiovascular disease is generally considered an inflammatory process and the analytics included are important determinates of cardiometabolic risk, particularly with respect to vascular inflammation.
Knowing your customized results for the YFH CCP test (including Homocysteine, C-Reactive Protein and Fasting Insulin) along with the Omega 3 Profile + test can change your future risk of heart disease. Taking the correct amount and type of fish oil is critical. Doing both tests at the same time provides the data to adjust your Omega3 intake. Making this adjustment can change your scores and reduce your risk factors in just two weeks.
Understanding Cholesterol and Lipoprotein
Cholesterol has historically been used as the standard indicator for cardiovascular disease, often being classified as “good” (HDL), or “bad” (LDL). Studies have found that it is actually the lipoprotein particles that carry the cholesterol through the blood, not the cholesterol within them, that are responsible for key steps in plaque formation and the development of cardiovascular disease. The small, dense, cholesterol-depleted particles impart the highest risk, as does an increased number of these lipoproteins. Standard cholesterol testing does not tell us enough about the particle types—or subgroups—of each of these LDL and HDL families; therefore, it misses the earliest opportunity to prevent adverse cardiovascular events, when it is easiest to treat.
Cardiovascular risk increases with a higher LDL particle count. The probability of particle penetration of the arterial walls rises, regardless of the total amount of cholesterol contained in each particle.
More than 30% of the population has cholesterol-depleted LDL, a condition in which a patient’s cholesterol may be “normal” but their lipoprotein particle number, and hence their actual risk, could be much higher than expected. This is especially common in people whose triglycerides are high or HDL is low.
There are twenty specific measures in this test. They include eight Lipoprotein Particle Markers, five Lipid Panel Markers and seven Vascular Inflammation Markers.
Cardiovascular disease is generally considered an inflammatory process and the analytics included are important determinates of cardiometabolic risk, particularly with respect to vascular inflammation.